Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
机构：[1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & PekingUnion Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,No.17 Panjiayuan Nanli, Chaoyang District, Beijing (100021), China[2]Department of Medical Oncology,Beijing Chest Hospital, Capital Medical University, Beijing (1011429), China[3]Department of RespirationMedicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking UnionMedical College, Beijing (100005), China[4]Department of Medical Oncology, Henan Cancer Hospital,Zhengzhou (450008), Henan Province, China河南省肿瘤医院[5]Department of Medical Oncology, Guangzhou ChestHospital, Guangzhou (510095), Guangdong Province, China[6]Cancer Center, Union Hospital, TongjiMedical College HuaZhong University of Science and Technology, Wuhan (430030), Hubei Province, China华中科技大学同济医学院附属协和医院[7]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang (050035),Hebei Province, China河北医科大学第四医院[8]Department of Medical Oncology, The 309th Hospital of Chinese People’sLiberation Army, Beijing (100091), China[9]Department of Medical Oncology, Nanfang Hospital, SouthernMedical University, Guangzhou (510515), Guangdong Province, China[10]Department of RespirationMedicine, Chinese People’s Liberation Army General Hospital, Beijing (100853), China[11]Department ofMedical Oncology, Liaoning Cancer Hospital, Shenyang (110042), Liaoning Province, China[12]Departmentof Medical Oncology, Sichuan Cancer Hospital, Chengdu (610041), Sichuan Province, China四川省肿瘤医院[13]Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan (250012), ShandongProvince, China[14]Department of Medical Oncology, The First Hospital of China Medical University,Shenyang (110001), Liaoning Province, China[15]Department of Medical Oncology, Shandong CancerHospital, Jinan (250117), Shandong Province, China[16]Department of Respiration Medicine, PekingUniversity First Hospital, Beijing (100034), China[17]Department of Medical Oncology, The First AffiliatedHospital of Dalian Medical University, Dalian (116011), Liaoning Province, China
Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective molecular epidemiology study in Asian patients with newly diagnosed advanced lung adenocarcinoma, aiming to prospectively analyze EGFR mutation status in IIIB/IV treatment-naive lung adenocarcinomas in Asia. We report the mainland China subset results. Eligible patients (similar to 20 yrs old, IIIB/IV adenocarcinoma and treatment-naive) were registered in 17 hospitals in mainland China. EGFR was tested for mutations by amplification refractory mutation system using biopsy samples. Demographic and clinical characteristics were collected for subgroup analyses. A total of 747 patients were registered. Successful EGFR mutation analysis was performed in 741, with an overall mutation rate of 50.2%. The EGFR active mutation rate is 48.0% (with 1.3% of combined active and resistance mutations). Tobacco use (>30 pack-year vs. 0-10 pack-year, OR 0.27, 95% CI: 0.17-0.42) and regional lymph nodes involvement (N3 vs. N0, OR 0.47, 95% CI: 0.29-0.76) were independent predictors of EGFR mutation in multivariate analysis. However, even in regular smokers, the EGFR mutation frequency was 35.3%. The EGFR mutation frequency was similar between diverse biopsy sites and techniques. The overall EGFR mutation frequency of the mainland China subset was 50.2%, independently associated with the intensity of tobacco use and regional lymph nodes involvement. The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged.
基金：
AstraZenecaAstraZeneca; Chinese National Major Project for New Drug Innovation [2008ZX09312, 2012ZX09303012-001]; Research Special Fund for Public Welfare Industry of Health [200902002-1]
第一作者机构：[1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & PekingUnion Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,No.17 Panjiayuan Nanli, Chaoyang District, Beijing (100021), China
通讯作者：
推荐引用方式(GB/T 7714)：
Yuankai Shi,Junling Li,Shucai Zhang,et al.Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study[J].PLOS ONE.2015,10(11):doi:10.1371/journal.pone.0143515.
APA：
Yuankai Shi,Junling Li,Shucai Zhang,Mengzhao Wang,Shujun Yang...&Xiaohong Han.(2015).Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.PLOS ONE,10,(11)
MLA：
Yuankai Shi,et al."Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study".PLOS ONE 10..11(2015)
